Each year, malaria occurs in approximately 225 million persons worldwide,
and 781,000 persons, mostly African children,die from the disease. During the past decade,the scale-up of malaria-control interventions has resulted in considerable reductions in morbidity and mortality associated with malaria
in parts of Africa. However, malaria continues to pose a major public health threat. A malaria vaccine, deployed in combination with current malaria-control tools, could play an important role in future control and eventual elimination of malaria Worldwide.
Study of the efficacy, safety, and immunogenicity of candidate
malaria vaccine RTS,S/AS01 conducted in seven African countries showed an efficacy of 56% in interim, phase III results published in the New England Journal of Medicine. The study was partially funded by and included scientist-employees of the vaccine maker. After 12 months of follow-up among 6000 African children vaccinated at age 5 to 17 months, the incidence of malaria was 0.44 per person-year among RTS,S/AS01 recipients and 0.83 among recipients of a control vaccine. Meningitis was more frequent among RTS,S/AS01 recipients.
An editorialist praises the work, while wondering about the duration of the vaccine's protection and its cost.
Read More
and 781,000 persons, mostly African children,die from the disease. During the past decade,the scale-up of malaria-control interventions has resulted in considerable reductions in morbidity and mortality associated with malaria
in parts of Africa. However, malaria continues to pose a major public health threat. A malaria vaccine, deployed in combination with current malaria-control tools, could play an important role in future control and eventual elimination of malaria Worldwide.
Study of the efficacy, safety, and immunogenicity of candidate
malaria vaccine RTS,S/AS01 conducted in seven African countries showed an efficacy of 56% in interim, phase III results published in the New England Journal of Medicine. The study was partially funded by and included scientist-employees of the vaccine maker. After 12 months of follow-up among 6000 African children vaccinated at age 5 to 17 months, the incidence of malaria was 0.44 per person-year among RTS,S/AS01 recipients and 0.83 among recipients of a control vaccine. Meningitis was more frequent among RTS,S/AS01 recipients.
An editorialist praises the work, while wondering about the duration of the vaccine's protection and its cost.
Read More
No comments:
Post a Comment